全口服直接抗病毒藥物Maviret治療台灣慢性C型肝炎病患的有效性和安全性

Effectiveness and Safety of All-Oral Direct-Acting Antiviral Agent, Maviret, for the Treatment of Taiwanese Patients with Chronic Hepatitis C

Maviret是一種全基因型，每日一次直接抗病毒藥物（DAA），用於治療慢性C型肝炎病毒（HCV）感染。此研究評估63位感染基因型1a、1b、2和6型HCV的台灣病人，使用Maviret治療8週或12週療程的有效性和安全性。結果顯示持續病毒反應（SVR）為98％，病人至治療終止均未出現與研究藥物相關的嚴重不良反應。總而言之，Maviret對於台灣代償性慢性C型肝炎病人的治療是安全且有效的。

Maviret is a pan-genotypic, once daily direct-acting antiviral (DAA) to treat patients with chronic hepatitis C virus (HCV) infection. In this study, we evaluated the efficacy and safety of 8-week or 12-week course of Maviret therapy in 63 Taiwanese patients who had HCV genotype 1a, 1b, 2 and 6 infection. The results showed the overall sustained virologic response (SVR) rate was 98%. None of our patients had serious adverse events related to study drug with discontinuation of therapy. In conclusion, Maviret is effective and safe for the treatment of Taiwanese patients with compensated chronic hepatitis C.